Nicholas Piramal India Inks R&D Deal With Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Mumbai-based Nicholas Piramal will develop two oncology targets for Merck and stands to receive up to $175 million per target plus royalties.